UNIGE document Scientific Article
previous document  unige:89774  next document
add to browser collection
Title

Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial

Authors
Lavigne-Lissalde, G
Aya, A G
Mercier, F J
Roger-Christoph, S
Chauleur, C
Morau, E
Ducloy-Bouthors, A S
Mignon, A
show hidden authors show all authors [1 - 15]
Published in Journal of Thrombosis and Haemostasis. 2015, vol. 13, no. 4, p. 520-529
Abstract Case reports on recombinant human factor VIIa (rhuFVIIa) use in women with severe postpartum hemorrhage (PPH) showed encouraging results, but no randomized controlled trial (RCT) is available.
Keywords AdultCoagulants/administration & dosage/adverse effects/therapeutic useCompassionate Use TrialsDinoprostone/analogs & derivatives/therapeutic useDrug Administration ScheduleFactor VIII/administration & dosage/adverse effects/therapeutic useFemaleFranceHemostatic Techniques/adverse effectsHumansHysterectomyInfusions, IntravenousPostpartum Hemorrhage/diagnosis/drug therapy/mortalityPregnancyRisk FactorsSeverity of Illness IndexSwitzerlandTime FactorsTreatment FailureVenous Thrombosis/chemically induced
Identifiers
PMID: 25594352
Full text
Article (Published version) (245 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Geneva Platelet Group (13)
Citation
(ISO format)
LAVIGNE-LISSALDE, G et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. In: Journal of Thrombosis and Haemostasis, 2015, vol. 13, n° 4, p. 520-529. https://archive-ouverte.unige.ch/unige:89774

73 hits

0 download

Update

Deposited on : 2016-12-02

Export document
Format :
Citation style :